• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Minorities Are Underrepresented in COVID-19 Trials, Expert Says

Minorities Are Underrepresented in COVID-19 Trials, Expert Says

June 8, 2020

Despite making up a large percentage of COVID-19 deaths, minorities are not seeing adequate enrollment in clinical trials for potential coronavirus treatments.

Edith Mitchell, director of the Sidney Kimmel Cancer Center at Jefferson’s Center to Eliminate Cancer Disparities and former president of the National Medical Association, claimed that studies of possible COVID-19 treatments are not enrolling enough minority participants, despite African Americans, who account for approximately 13 percent of the population, dying from the virus twice as frequently as other racial and ethnic groups.

A multinational registry analysis of the use of hydroxychloroquine or chloroquine with or without a macrolide that analyzed data from 671 hospitals on six continents showed that of the 96,032 patients whose data were evaluated, only 5,978 (6 percent) were Hispanic, 9,054 (9 percent) were black and 13,519 (14 percent) were Asian.

Additionally, a preliminary report for a 1,063-patient, placebo-controlled trial of remdesivir conducted by the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) enrolled only 134 (12.6 percent) Asian, 219 (20.6 percent) black and 249 (23.4 percent) Hispanic or Latino participants.

At a WCG Clinical webinar last week, Mitchell recommended ways for COVID-19 trials to adequately enroll minorities, including prioritizing their inclusion, developing a formal diversity strategy for recruitment and, during site selection, working with institutions that have connected with minority communities and possess the infrastructure to conduct research.

Trials can also partner with local community organizations, such as churches and other “trust bearers,” to help circulate trial awareness and accessibility, and work with institutions that serve underrepresented populations. In addition, they should consider creating a multilingual targeted recruitment plan for minority communities, she said.

Those tactics can help tackle the representative enrollment issue in the future, she said, adding that looking forward, researchers should foster relationships with minority-based health organizations, community groups and others with close knowledge of minority communities, and work with institutions and investigators that use diversity enrollment plans and prioritize diversifying their trials.

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing